Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Multiple Myeloma 2Solid Tumors 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Lung Neoplasms 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 30Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Radiotherapy 16Pemetrexed 15Albumin-Bound Paclitaxel 15Nivolumab 13Ramucirumab 11Cyclophosphamide 11Drug Therapy 9Trastuzumab 8Erlotinib Hydrochloride 8zolbetuximab 7Taxes 7Radiosurgery 7trastuzumab deruxtecan 6cemiplimab 6Blood Specimen Collection 6regorafenib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × LCL161 × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡